Sato Akira, Hoshi Tomoya, Kakefuda Yuki, Harunari Tomohiko, Watabe Hiroaki, Hiraya Daigo, Akiyama Daiki, Abe Daisuke, Takeyasu Noriyuki, Aonuma Kazutaka
Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
J Cardiol. 2015 Nov;66(5):417-22. doi: 10.1016/j.jjcc.2014.12.016. Epub 2015 Jan 23.
The association of Mehran risk score (MRS) with long-term prognosis in patients treated with percutaneous coronary intervention (PCI) has not been fully reported. We investigated the association between MRS and clinical outcomes in patients who underwent PCI.
Study subjects comprised 2198 patients treated with PCI from the Ibaraki Cardiovascular Assessment Study multicenter registry, excluding patients receiving hemodialysis or who died within 7 days. We categorized them into 4 groups according to MRS (low-risk: ≤5; medium-risk: 6-10; high-risk: 11-16; and very high-risk: ≥16). Contrast-induced acute kidney injury (CI-AKI) was defined as an increase of 0.5mg/dL or 25% in pre-PCI serum creatinine within 1-week post procedure. We evaluated CI-AKI and major adverse cardiac and cerebrovascular events (MACCE), and defined as all-cause death, myocardial infarction, congestive heart failure, or cerebrovascular disorder (stroke or transient ischemic attack).
A total of 192 (8.7%) patients developed CI-AKI. At multivariate analysis, odds ratio for CI-AKI was 4.09 (95% CI: 1.72-9.17, p=0.002) in the very high-risk group, 1.49 (95% CI: 0.89-2.42, p=0.120) in the high-risk group, and 1.08 (95% CI: 0.74-1.54, p=0.693) in the medium-risk group, as compared with the low-risk group. MACCE in the very high-risk group was more than 5-fold higher [hazard ratio (HR) 5.40, 95% CI: 2.96-9.28, p<0.001] compared with the low-risk group and was also increased in the high-risk (HR 3.72, CI: 2.59-5.32, p<0.001) and medium-risk groups (HR 1.97, CI: 1.45-2.69, p<0.001). Kaplan-Meier analysis showed that increasing risk for MACCE was seen across the groups as MRS increased (p<0.001).
MRS might provide potentially useful information for prediction of CI-AKI and clinical outcomes after PCI.
经皮冠状动脉介入治疗(PCI)患者的梅兰风险评分(MRS)与长期预后的关联尚未得到充分报道。我们调查了接受PCI患者中MRS与临床结局之间的关联。
研究对象包括来自茨城县心血管评估研究多中心登记处的2198例接受PCI治疗的患者,排除接受血液透析或在7天内死亡的患者。我们根据MRS将他们分为4组(低风险:≤5;中风险:6 - 10;高风险:11 - 16;极高风险:≥16)。对比剂诱导的急性肾损伤(CI - AKI)定义为术后1周内PCI术前血清肌酐升高0.5mg/dL或升高25%。我们评估了CI - AKI和主要不良心脑血管事件(MACCE),MACCE定义为全因死亡、心肌梗死、充血性心力衰竭或脑血管疾病(中风或短暂性脑缺血发作)。
共有192例(8.7%)患者发生CI - AKI。在多变量分析中,与低风险组相比,极高风险组发生CI - AKI的比值比为4.09(95%可信区间:1.72 - 9.17,p = 0.002),高风险组为1.49(95%可信区间:0.89 - 2.42,p = 0.120),中风险组为1.08(95%可信区间:0.74 - 1.54,p = 0.693)。与低风险组相比,极高风险组的MACCE高出5倍多[风险比(HR)5.40,95%可信区间:2.96 - 9.28,p < 0.001],高风险组(HR 3.72,可信区间:2.59 - 5.32,p < 0.001)和中风险组(HR 1.97,可信区间:1.45 - 2.69,p < 0.001)的MACCE也有所增加。Kaplan - Meier分析表明,随着MRS增加,各组MACCE风险均升高(p < 0.001)。
MRS可能为预测PCI术后CI - AKI和临床结局提供潜在有用的信息。